Adlyxin is manufactured by Sanofi-Aventis U.S. LLC, of Bridgewater, New Jersey.
Adlyxin with an active ingredient lixisenatide is the new drug approved by U.S. Food and Drug Administration on July 28, 2016. This drug is approved in parentral dosage form. It's dosage frequency is once a day and injected through subcutaneous route. Adlyxin/lixisenatide belongs to a class of drug called as a glucagon-like peptide-1 (GLP-1) receptor agonist. GLP-1 is hormone that helps in the regulation of blood sugar control.
Type 2 diabetes is a common problem in US population. In type 2 diabetes, insulin produces at normal level but insulin sensing receptors present in liver, kidney and other organ tissues become desensitize. This desensitization leads to improper or poor attachment of insulin at insulin bind receptors. Ultimately, patient loses his control over blood sugar and becomes diabetic.
Adlyxin is aimed to improve blood sugar level along with exercise and dietary control because no single pill can efficiently control blood sugar control without taking further measures. Type 2 diabetes is a kind of disease that can be managed by taking medications along with life style modifications.
During clinical trails Adlyxin safety profile was quite satisfactory. Adlyxin is quite safe for patient having types 2 diabetes along with atheroseclerosis ( stenosis of arteries). Adlyxin helps to improve blood sugar level with no harm to cardiac issues like angina, atrial fibrillation, tachycardia, thromboembolic phenomenon and atherosclerosis.
Adlyxin was tested for possible side effects during clinical trials. These side effects were mild moderate.
However, this drug was also tested as standalone therapy during clinical trials in which it is showed promising results. Adlyxin should not be used to treat people with type 1 diabetes or patients with increased ketones in their blood or urine (diabetic ketoacidosis).
Now, on day 15 use burgundy pen as maintenance dose. Burgundy pen is also 3mL prefilled pen and each ml contains 100mcg/ml dose. It is used as maintenance dose. It provides 14 doses of 20mcg/dose. Inject subcutaneously 20mcg/day for 14 days.
Adlyxin with an active ingredient lixisenatide is the new drug approved by U.S. Food and Drug Administration on July 28, 2016. This drug is approved in parentral dosage form. It's dosage frequency is once a day and injected through subcutaneous route. Adlyxin/lixisenatide belongs to a class of drug called as a glucagon-like peptide-1 (GLP-1) receptor agonist. GLP-1 is hormone that helps in the regulation of blood sugar control.
Type 2 diabetes is a common problem in US population. In type 2 diabetes, insulin produces at normal level but insulin sensing receptors present in liver, kidney and other organ tissues become desensitize. This desensitization leads to improper or poor attachment of insulin at insulin bind receptors. Ultimately, patient loses his control over blood sugar and becomes diabetic.
Adlyxin is aimed to improve blood sugar level along with exercise and dietary control because no single pill can efficiently control blood sugar control without taking further measures. Type 2 diabetes is a kind of disease that can be managed by taking medications along with life style modifications.
During clinical trails Adlyxin safety profile was quite satisfactory. Adlyxin is quite safe for patient having types 2 diabetes along with atheroseclerosis ( stenosis of arteries). Adlyxin helps to improve blood sugar level with no harm to cardiac issues like angina, atrial fibrillation, tachycardia, thromboembolic phenomenon and atherosclerosis.
Adlyxin/lixisenatide Side effects
Adlyxin was tested for possible side effects during clinical trials. These side effects were mild moderate.
- Nausea
- Vomiting
- Headache
- Diarrhea
- Dizziness
- Hypersensitivity
- Anaphylaxis
- Asthenia
- Muscle Weakness
- Mild Fever
- Rash at injection site
- Loss of appetiteÂ
 Adlyxin/lixisenatide Uses/Prescribing InformationÂ
US FDA approved Adlyxin to control blood sugar level in type 2 diabetes. Adlyxin gives better control over blood sugar level if it used with other diabetes medications following life style modifications and dietary restrictions.However, this drug was also tested as standalone therapy during clinical trials in which it is showed promising results. Adlyxin should not be used to treat people with type 1 diabetes or patients with increased ketones in their blood or urine (diabetic ketoacidosis).
 Adlyxin/lixisenatide Dosage
Adlyxin/lixisenatide pack contains two types of pen. One is green pen and other is bugendy pen. Green pen is 3mL prefilled pen and each ml contains 50mcg/ml dose. It is used as starter dose. It provides 14 dose of 10mcg/dose. Start with green pen and inject subcutaneously 10mcg/day for 14 days.Now, on day 15 use burgundy pen as maintenance dose. Burgundy pen is also 3mL prefilled pen and each ml contains 100mcg/ml dose. It is used as maintenance dose. It provides 14 doses of 20mcg/dose. Inject subcutaneously 20mcg/day for 14 days.
0 Comments
For comments please reply here.......